SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) such as empagliflozin, dapagliflozin, and canagliflozin represent excellent alternatives, providing cardiovascular and renal protection alongside modest weight loss (typically 2-4 kg)
On the same ground, in contrast to the control group, the POI groups steroidogenic genes, such as STAR, CYP17A1, and HSD17B3, were significantly downregulated, according to the studys findings
Given that peptide users today are self-selected and tend to be young and healthy, their response may not be translatable to the general patient population who may have more medical comorbidities, Frank said
Ill share more of this journey on TikTok @drterrysimpson and Instagram @drterrysimpsonmd
Designed to avoid off-target hormone spikes, so your fat-metabolism results stay specific
Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Soeborg H, and Knudsen LB